No new treatments for #schizophrenia have been approved in nearly three decades, but that changed on Sept. 26, when the U.S. Food and Drug Administration (FDA) approved #Cobenfy for the psychiatric disorder.
Developed by Karuna Therapeutics, which was subsequently acquired by Bristol Myers Squibb, the drug works in an entirely different way from existing medications for schizophrenia.
1/
@thewebrecluse
This is good news, I hope it’s not stupidly expensive and that it doesn’t have a lot of side effects.
Follow
@Smccune55 we are talking about the American For Profit Pharma business so ... obviously both things will be true.